SRC and neuroblastoma: Notably, there is an additional example were bosutinib was similarly repurposed against neuroblastoma, where it was shown capable of suppressing oncogenic activity via targeting multiple signaling pathways including Src/Abl and PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT3 [146].